HOME >> MEDICINE >> NEWS
Humble Planaria worm offers ideal model for drug withdrawal research

Through the humble Planaria worm, Temple University researchers hope to discover what happens when drug abusers who take more than one drug-a common practice-go into withdrawal. Their work, which is funded by a new $450,000, three-year grant from the National Institutes of Health, is expected to lead to a better understanding of how withdrawal is influenced by poly-drug abuse and someday to the development of better treatment.

"People who abuse drugs tend to abuse many different drugs, yet much of the current research in the field focuses on single drug abuse," explained primary investigator, Robert Raffa, Ph.D., professor of pharmacology at Temple University School of Pharmacy.

Typically, abusers take several drugs together to multiply the pleasurable effects or manage the undesirable effects-for instance, using alcohol with cocaine. Because each type of drug affects the body differently, withdrawal is more complicated when more than one is involved. It would be impossible to conduct controlled scientific research on human subjects, so scientists have sought out alternatives.

As a study subject, the Planaria worm, a type of flatworm known for its regenerative powers, has several qualities attractive to scientists. First, it has such simple biochemistry and it readily absorbs any chemical in which it is soaked. This simplicity makes it a clean, easy-to-use model. But despite this simplicity, the Planaria worm has a brain and spinal cord, both key to studying the effects of drug abuse and withdrawal. Furthermore, Planaria have the same types of neurotransmitter systems as humans and thus respond to dopamine, opioids, cocaine and cannabinoids.

"Planaria offer a clean and uncomplicated model. We don't have to worry about potential interference from other organs or organ systems, as would be the case in other animal models," said Raffa. "Plus, Planaria display amazing behaviors. They can even learn."

Some might reme
'"/>

Contact: Eryn Jelesiewicz
dobeck@temple.edu
215-707-0730
Temple University
29-Nov-2004


Page: 1 2

Related medicine news :

1. UCSF study offers insight into human circadian rhythms
2. Research offers hope of new treatments for liver damage
3. Portable system offers dialysis patients liberating changes
4. New laparoscopic hysterectomy offers quicker recovery time than traditional surgery
5. UIC offers new weight loss surgery for obese teens
6. COX-2 product offers good and bad news in test tube strokes
7. Clinical breast examination offers modest benefit to breast cancer screening program
8. Research offers hope of new treatments for liver damage plague
9. Herpes virus offers new hope in curing cancer
10. Panel offers recommendations for monitoring adverse events from dietary supplements
11. Improved acute lymphoblastic leukemia treatment offers hope for eliminating irradiation

Post Your Comments:
(Date:10/31/2014)... Monica Williams-Murphy MD , advanced care ... the chaos that can occur for people who have ... of Americans who come into the emergency department facing ... for the moment and so are their families." She ... a catalyst for a family to get the critical ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: